The HARMONY Alliance is a public-private European Network of Excellence, established in January 2017. HARMONY consisting of experts aiming to transform the treatment of haematological malignancies, known as HMs.
The mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.
HARMONY currently have 53 Partners and 37 Associated Members from 22 countries, including 8 pharmaceutical companies and 7 European Patient Umbrella Organizations.
The HARMONY Alliance is orchestrating the consolidation of all databases into one common platform. This will harness the enormous potential of BigData and BigData analytics to deliver insights into how the care of patients with blood cancers can be improved.
HARMONY’s partners from industry are providing access to clinical trials data, showing how drugs work in controlled circumstances. Public registries collect data on how patients are treated and the outcomes of therapies in the real world. Together, these sources are greater than the sum of their parts. For example, by combining the populations from several clinical trials, it is possible to analyze populations with rare diseases with greater statistical power than individual databases can provide.
Other Big Data analyses can reveal molecular data on genomes, what proteins are expressed in different cancers, how treatments affect the expression of important genes, and more.
EAPM has contributed to the definition and realisation of a White Paper that defines the policy strategy and, in particular, describes the role of Big Data in haematology and the HARMO-NY Alliance in overcoming key obstacles to efficient treatment of HMs.
We have reported on the progress on relevant items so far, and the recommendations for the future. Down the line, a General Assembly was held in Florence in late September 2019.
PIONEER is a European Network of Excellence for Big Data in Prostate Cancer, consisting of 32 partners across 9 countries.
PIONEER’s goal is to develop, and validate, an EU-wide evidence framework for the value assessment of innovative technologies in prostate cancer, using real-world evidence.
PIONEER’s unique approach is to firstly identify critical evidence gaps in prostate cancer care through a detailed prioritisation exercise including all stakeholders (i.e. clinicians, patients, researchers, industry etc.).
PIONEER will then standardise and integrate existing ‘big data’ from high quality and multidisciplinary data sources from prostate cancer patients across different stages of the disease into a single innovative data platform. Based on a unique set of methodologies and advanced analytical methods, PIONEER will attempt to transform the field of prostate cancer care with particular focus on improving prostate cancer-related outcomes, health system efficiency and the quality of health and social care delivered to all prostate cancer patients and their families. In addition, PIONEER will aim to provide standardised care pathways for all clinical centres across Europe.
EAPM is co-lead of WP6, this WP has committed to developing a prostate-cancer-specific framework for evidence requirements to support the efficient and targeted use of current treatment options in addition to the appropriate introduction and adoption of new technologies.
Against this background, EAPM developed the first policy paper defining the project’s strategy and priorities. May 2019 saw a two-day General Assembly held in Berlin, with the Alliance taking the lead in the HTA and payer aspects.
DIGITAL HEALTH EUROPE
DigitalHealthEurope will provide comprehensive support to the Digital Health and Care Innovation initiative in the context of the Digital Single Market Strategy. The project's approach involves a number of actions that will boost innovation and advance the Digital Single Market priorities for the digital transformation of health and care(DTHC), as outlined in the European Commission's 2018 Communication on the topic. The priorities concern:
- citizens’ secure access to and sharing of health data across borders
- better data to advance research, disease prevention and personalised health and care
- digital tools for citizen empowerment and person-centred care.
To achieve these three priorities, the project work plan offers two forms of support.
Together, they will form a common vision of EU coordination and support for DTHC beyond 2020.
Support to large scale deployment of digital solutions for person-centred integrated care
DigitalHealthEurope's main objective the deployment of digital solutions for person-centred integrated care. Assessment tools will be used to identify, analyse and select successful initiatives which are highly impactful and replicable. DigitalHealthEurope will also provide structured advice on EU funding instruments and financing sources. The selected initiatives will have the opportunity to pursue replication and scaling-up. This will be done with the aid of instruments such as matchmaking and a twinning support scheme.
Support to DTHC innovation through collaboration in multi-stakeholder communities.
DigitalHealthEurope will also facilitate the creation of a shared platform for multi-stakeholder communities. These communities directly address the three priorities.
Each of the communities will carry out concrete activities. With the help of associated experts and contributors, they will provide key DHE outcomes such as white papers, guidelines and policy recommendations.
DigitalHealthEurope will ensure the mutual flow of information between the two support activities.
The results will be channelled into drafting a roadmap, advice and recommended actions.
With regards to DIGITAL HEALTH EUROPE EAPM is responsible for tasks that prioritise infrastructure capabilities and enablers to ensure EU-wide cross-border access and exchange of genomic and other health data.
Meanwhile, an ongoing series of surveys, six in all, are being launched throughout the year to garner feedback from a range of experts in our field.
Name of the project and grant agreement: Personalized Medicine Inquiry-Based Education (PROMISE); Grant agreement: br. 2019-1-HR01-KA203-061010
Coordinating institution: Mediterranean Institute for Life Sciences (MedILS)
Project partners: School of Medicine of the University of Split (UNIST); Faculty of Science and Faculty of Pharmacy and Biochemistry, University of Zagreb (UNIZG); Pompeu Fabra University (UPF); European Alliance of Personalized Medicine (EAPM); Tamara Milosevic
Short summary of the project: The project is focused on the development of 4 "plug and play" blended-learning online modules, each covering a P in P4 medicine in light of the Responsible Research and Innovation principles.
Project's objectives: The main objective of the PROMISE project is to prepare medical and science students for the rapidly changing landscape of medical practice and research by creating innovative teaching tools and practices for inquiry-based online learning of P4 Medicine and Responsible Research and Innovation principles. This approach requires cross-disciplinary culture and the change towards a proactive mindset from a traditional "fixed" evidence-based approach to treating patients.
Expected results: To promote the appropriate training that develops the P4 medicine understanding and the skills to implement this new approach in medical schools and science programs in order to construct a cohesive basis of knowledge and skills that can be delivered as online and blended learning programs.
Grant: 263 000.00 EUR for 2 years
Financing organism: Co-funded by the Erasmus+ Programme of the European Union http://www.mobilnost.hr/en/
Call: Cooperation for innovation and the exchange of good practices - Strategic Partnerships for higher education
Implementation period-duration of the project: 01/10/2019 - 30/09/2021
Contact person: Mediterraean institute for life sciences
Dr. Branka Bernard; project manager